Beruflich Dokumente
Kultur Dokumente
Pharmacovigilance Program
Annexure-I
Pharmacovigilance
Clinical trials are limited in time and number of patients. They are largely artificial
because patients are selected based on stringent criteria e.g patients are adult, taking no
other medicines and with essentially no other diseases. Therefore, the subset of
population selected for clinical trials may not always represent the real life use of drugs.
Rare and delayed serious reactions are likely to remain unnoticed during clinical trials.
Improvement of patient care and safety in relation to the use of medicines and all medical
and paramedical interventions
The assessment of benefit, harm, effectiveness and risk of medicines, encouraging their
safe, rational and more effective (cost effective) use
Identifiable Patient
Identifiable Reporter
Suspected Drug Name
Adverse Drug Reaction Term/ Description
You do not need to be certain, just suspicious to report.
Pharmacovigilance Program
http://ec.europa.eu/enterprise/pharmaceuticals/eudralex/homev9.htm